Cue Biopharma discloses $49.99 million private securities offering
A Form D filed with the SEC shows Cue Biopharma raised nearly $50 million from four investors in an exempt offering dated July 13, 2026.
Cue Biopharma, Inc., based in Boston, Massachusetts, filed a Form D notice with the Securities and Exchange Commission dated July 22, 2026, disclosing a private securities offering. The filing marks a new notice with a date of first sale listed as 2026-07-13.1
The offering totaled $49,999,927 in total offering amount, with the same amount, $49,999,927, reported as sold and $0 remaining to be sold.1 The company reported a total of four investors who had already invested in the offering.1
The filing indicates the securities offered included equity, an option, warrant or other right to acquire another security, and a security to be acquired upon exercise of such an option, warrant, or right.1 Cue Biopharma claimed exemption under Rule 506(b) of Regulation D.1
The company stated the offering was not tied to a business combination transaction, as the filing shows the "no" box checked for whether the offering was made in connection with a merger, acquisition or exchange offer.1 No sales commissions or finder's fees were reported, with the filing listing $0 in sales commissions and $0 in finders' fees.1 Similarly, the amount of gross proceeds proposed for payments to executive officers, directors or promoters was listed as $0.1
Related persons named in the filing include Shao-Lee Lin, Dominic Borie, and Sumita Ray, each listed as executive officers, along with several individuals listed as directors, including Daniel Camardo, Pamela Garzone, Viola Meehan, and Pasha Sarraf. The notice was signed by Sumita Ray, JD, Chief Legal & Compliance Officer, on 2026-07-22.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.